Maximillian A Rogers1, Joshua D Hutcheson1, Takehito Okui1, Claudia Goettsch1, Sasha A Singh1, Arda Halu1, Florian Schlotter1, Hideyuki Higashi1, Lixiang Wang2, Mary C Whelan1, Andrew K Mlynarchik1, Alan Daugherty3, Masatoshi Nomura4, Masanori Aikawa1,5, Elena Aikawa1,5,6. 1. Center for Interdisciplinary Cardiovascular Sciences, Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA. 2. Department of Medical Biochemistry, Kurume University School of Medicine, Kurume 830-0011, Japan. 3. Saha Cardiovascular Research Center and Department of Physiology, University of Kentucky, Lexington, KY 40536, USA. 4. Division of Endocrinology and Metabolism, Department of Internal Medicine, Kurume University School of Medicine, Kurume 830-0011, Japan. 5. Center for Excellence in Vascular Biology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA. 6. Department of Human Pathology, Sechenov First Moscow State Medical University, Moscow 119992, Russia.
Abstract
AIMS: Proteostasis maintains protein homeostasis and participates in regulating critical cardiometabolic disease risk factors including proprotein convertase subtilisin/kexin type 9 (PCSK9). Endoplasmic reticulum (ER) remodeling through release and incorporation of trafficking vesicles mediates protein secretion and degradation. We hypothesized that ER remodeling that drives mitochondrial fission participates in cardiometabolic proteostasis. METHODS AND RESULTS: We used in vitro and in vivo hepatocyte inhibition of a protein involved in mitochondrial fission, dynamin-related protein 1 (DRP1). Here, we show that DRP1 promotes remodeling of select ER microdomains by tethering vesicles at ER. A DRP1 inhibitor, mitochondrial division inhibitor 1 (mdivi-1) reduced ER localization of a DRP1 receptor, mitochondrial fission factor, suppressing ER remodeling-driven mitochondrial fission, autophagy, and increased mitochondrial calcium buffering and PCSK9 proteasomal degradation. DRP1 inhibition by CRISPR/Cas9 deletion or mdivi-1 alone or in combination with statin incubation in human hepatocytes and hepatocyte-specific Drp1-deficiency in mice reduced PCSK9 secretion (-78.5%). In HepG2 cells, mdivi-1 increased low-density lipoprotein receptor via c-Jun transcription and reduced PCSK9 mRNA levels via suppressed sterol regulatory binding protein-1c. Additionally, mdivi-1 reduced macrophage burden, oxidative stress, and advanced calcified atherosclerotic plaque in aortic roots of diabetic Apoe-deficient mice and inflammatory cytokine production in human macrophages. CONCLUSIONS: We propose a novel tethering function of DRP1 beyond its established fission function, with DRP1-mediated ER remodeling likely contributing to ER constriction of mitochondria that drives mitochondrial fission. We report that DRP1-driven remodeling of select ER micro-domains may critically regulate hepatic proteostasis and identify mdivi-1 as a novel small molecule PCSK9 inhibitor. Published on behalf of the European Society of Cardiology. All rights reserved.
AIMS: Proteostasis maintains protein homeostasis and participates in regulating critical cardiometabolic disease risk factors including proprotein convertase subtilisin/kexin type 9 (PCSK9). Endoplasmic reticulum (ER) remodeling through release and incorporation of trafficking vesicles mediates protein secretion and degradation. We hypothesized that ER remodeling that drives mitochondrial fission participates in cardiometabolic proteostasis. METHODS AND RESULTS: We used in vitro and in vivo hepatocyte inhibition of a protein involved in mitochondrial fission, dynamin-related protein 1 (DRP1). Here, we show that DRP1 promotes remodeling of select ER microdomains by tethering vesicles at ER. A DRP1 inhibitor, mitochondrial division inhibitor 1 (mdivi-1) reduced ER localization of a DRP1 receptor, mitochondrial fission factor, suppressing ER remodeling-driven mitochondrial fission, autophagy, and increased mitochondrial calcium buffering and PCSK9 proteasomal degradation. DRP1 inhibition by CRISPR/Cas9 deletion or mdivi-1 alone or in combination with statin incubation in human hepatocytes and hepatocyte-specific Drp1-deficiency in mice reduced PCSK9 secretion (-78.5%). In HepG2 cells, mdivi-1 increased low-density lipoprotein receptor via c-Jun transcription and reduced PCSK9 mRNA levels via suppressed sterol regulatory binding protein-1c. Additionally, mdivi-1 reduced macrophage burden, oxidative stress, and advanced calcified atherosclerotic plaque in aortic roots of diabetic Apoe-deficient mice and inflammatory cytokine production in human macrophages. CONCLUSIONS: We propose a novel tethering function of DRP1 beyond its established fission function, with DRP1-mediated ER remodeling likely contributing to ER constriction of mitochondria that drives mitochondrial fission. We report that DRP1-driven remodeling of select ER micro-domains may critically regulate hepatic proteostasis and identify mdivi-1 as a novel small molecule PCSK9 inhibitor. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Ann Cassidy-Stone; Jerry E Chipuk; Elena Ingerman; Cheng Song; Choong Yoo; Tomomi Kuwana; Mark J Kurth; Jared T Shaw; Jenny E Hinshaw; Douglas R Green; Jodi Nunnari Journal: Dev Cell Date: 2008-02 Impact factor: 12.270
Authors: Ying Wang; Manikandan Subramanian; Arif Yurdagul; Valéria C Barbosa-Lorenzi; Bishuang Cai; Jaime de Juan-Sanz; Timothy A Ryan; Masatoshi Nomura; Frederick R Maxfield; Ira Tabas Journal: Cell Date: 2017-09-21 Impact factor: 41.582
Authors: Danchen Wu; Asish Dasgupta; Kuang-Hueih Chen; Monica Neuber-Hess; Jignesh Patel; Timothy E Hurst; Jeffrey D Mewburn; Patricia D A Lima; Elahe Alizadeh; Ashley Martin; Michael Wells; Victor Snieckus; Stephen L Archer Journal: FASEB J Date: 2019-12-02 Impact factor: 5.191